Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorethamine in relapsed/refractory Hodgkin lymphoma (HL)

被引：1
|
作者：
Carlo-Stella, C.
Guidetti, A.
Viviani, S.
Bonfante, V.
Marchiano, A.
Gatti, B.
D'Urzo, C.
Di Nicola, M. A.
Corradini, P.
Gianni, A. M.
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Univ Milan, Milan, Italy
[3] Italfarmaco SpA, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3068
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Safety and Efficacy of Tinostamustine in Heavily Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)
    Ghesquieres, Herve
    Pinto, Antonio
    Sureda, Anna
    Tournilhac, Olivier
    Morschhauser, Franck
    Janik, Tomas
    Zinzani, Pier Luigi
    BLOOD, 2021, 138
  • [32] ESHAP vs GIN as salvage and mobilizing regimens in relapsed or refractory Hodgkin Lymphoma (HL)
    Tsirkinidis, P.
    Vassilakopoulos, T. P.
    Moschoyiannis, M.
    Galanis, Z.
    Anargyrou, K.
    Dimitriadou, E.
    Masouridis, S.
    Pappis, V.
    Gratsias, N.
    Chatzileonidas, E.
    Sachanas, S.
    Kalotychou, V.
    Kostandoudakis, K.
    Kokoris, S.
    Siakantaris, M.
    Rombos, I.
    Pangalis, G. A.
    Angelopoulou, M. K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 79 - 79
  • [33] ESHAP VS IGEV AS SALVAGE AND MOBILIZING REGIMENS IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL)
    Tsirkinidis, P.
    Vassilakopoulos, T.
    Tsopra, O.
    Pappis, V.
    Moschoyianni, M.
    Galani, Z.
    Anargyrou, K.
    Vardounioti, I.
    Dimitrakopoulou, A.
    Masouridis, M.
    Kyrtsonis, M. C.
    Panayiotidis, P.
    Pangalis, G.
    Beris, P.
    Angelopoulou, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 368 - 368
  • [34] Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma
    Kim, Miryoung
    Thompson, Lisa A.
    Wenger, Sarah D.
    O'Bryant, Cindy L.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (10) : 1340 - 1348
  • [35] A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
    Evens, Andrew M.
    Balasubramanian, Sriram
    Vose, Julie M.
    Harb, Wael
    Gordon, Leo I.
    Langdon, Robert
    Sprague, Julian
    Sirisawad, Mint
    Mani, Chitra
    Yue, Jeanne
    Luan, Ying
    Horton, Sharon
    Graef, Thorsten
    Bartlett, Nancy L.
    CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1059 - 1066
  • [36] Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma
    Evens, Andrew M.
    Brandt, Justin S.
    Peer, Cody J.
    Yin, Tyler
    Schaar, Dale
    Farooq, Faheem
    Mozarsky, Brett
    Figg, William D.
    Sharon, Elad
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : 833 - 838
  • [37] Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
    Forlenza, Christopher J.
    Gulati, Nitya
    Mauguen, Audrey
    Absalon, Michael J.
    Castellino, Sharon M.
    Franklin, Anna
    Keller, Frank G.
    Shukla, Neerav
    BLOOD ADVANCES, 2021, 5 (24) : 5519 - 5524
  • [38] Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies
    Ganai, Shabir Ahmad
    JOURNAL OF CHEMOTHERAPY, 2016, 28 (04) : 247 - 254
  • [39] PHASE II STUDY OF THE HISTONE-DEACIETYLASE INHIBITOR ITF2357 IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA PATIENTS
    Bonfante, V.
    Viviani, S.
    Fasola, C.
    Crippa, F.
    Marchiano, A.
    Valagussa, P.
    Gianni, A. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 244 - 244
  • [40] Durable complete remission after brentuximab vedotin in a patient with relapsed and refractory Hodgkin lymphoma (HL)
    Drach J.
    Huk I.
    Lamm W.
    memo - Magazine of European Medical Oncology, 2013, 6 (2) : 119 - 122
12345